SIGA Technologies - BARDA exercises first option for IV TPOXX
Following strong Q222 results, SIGA Technologies has announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first procurement option for intravenous (IV) TPOXX, worth $26m, under its 19C contract signed in September 2018. The contract includes manufacturing and delivery of up to 212,000 courses of IV TPOXX to the US strategic stockpile over the 10-year contractual term. SIGA delivered the first c 20,000 courses in Q122 and the announced procurement is the first of the IV TPOXX options (64,000 courses each; c $400/course). The product delivery on this option exercise is targeted for 2023. IV TPOXX received FDA approval in May 2022 and expands the company’s addressable market to those who are unable to take the oral formulation (either too sick or unable to swallow).SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.